<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-148945" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Setmelanotide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hussain</surname>
            <given-names>Azhar</given-names>
          </name>
          <aff>Touro College of Pharmacy</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farzam</surname>
            <given-names>Khashayar</given-names>
          </name>
          <aff>McMaster University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Azhar Hussain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khashayar Farzam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-148945.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Setmelanotide is a medication that acts on the melanocortin-4 receptor (MC4R) for the treatment of severe obesity caused by genetic disorders, including deficiency of proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR). This activity reviews the indication, mechanism of action, adverse events, contradiction, monitoring, and toxicity of setmelanotide therapy, which can provide essential information to the clinical team members responsible for managing the care of patients with severe obesity and its related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the mechanism of action of setmelanotide.</p></list-item><list-item><p>Identify the most common adverse effects of setmelanotide therapy.</p></list-item><list-item><p>Summarize the contraindication associated with setmelanotide therapy.</p></list-item><list-item><p>Outline the indication, monitoring, and toxicity associated with setmelanotide.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148945&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148945">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-148945.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Setmelanotide is the first available anorexigenic agent, a melanocortin-4 receptor (MC4R) agonist for treating obesity caused by a rare genetic disorder.<xref ref-type="bibr" rid="article-148945.r1">[1]</xref>&#x000a0;Setmelanotide was approved by the Food and Drug Administration (FDA) on November 25, 2020, for the indication of chronic weight management in adults and pediatrics six years of age and older due to the deficiency of proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.<xref ref-type="bibr" rid="article-148945.r1">[1]</xref><xref ref-type="bibr" rid="article-148945.r2">[2]</xref>&#x000a0;</p>
        <p>Setmelanotide allows weight loss in patients with these genetic obesity disorders by restoring appetite control, thereby reducing food intake and weight gain. However, setmelanotide does not treat these hereditary defects which cause obesity.<xref ref-type="bibr" rid="article-148945.r3">[3]</xref></p>
      </sec>
      <sec id="article-148945.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The deficiencies or mutations in the POMC, PCSK1, or LEPR have been shown to cause hyperphagia resulting in severe childhood-onset obesity leading to multiple endocrinopathies, including adrenocorticotropic hormone deficiency, hypothyroidism, hypogonadism, hypopigmentation, hypoglycemia.<xref ref-type="bibr" rid="article-148945.r2">[2]</xref><xref ref-type="bibr" rid="article-148945.r4">[4]</xref>&#x000a0;Setmelanotide is a disulfide cyclic octapeptide that can cross the blood-brain barrier and act on the hypothalamus. It&#x000a0;is metabolized into small peptides and amino acids by catabolic pathways with an elimination half-life (t1/2) of approximately 11 hours. Approximately 39% of the administrated drug dose is excreted in the urine unchanged within 24 hours.<xref ref-type="bibr" rid="article-148945.r5">[5]</xref>&#x000a0;</p>
        <p>Setmelanotide can bind to and activates multiple melanocortin receptors, including melanocortin-4 receptor (MC4R), melanocortin-3 receptor (MC3R), and melanocortin-1 receptor (MC1R) selectively over melanocortin-2 receptor (MC2R) and melanocortin-5 receptor (MC5R).<xref ref-type="bibr" rid="article-148945.r6">[6]</xref>&#x000a0;These melanocortin receptor systems consist of five 7-transmembrane G-protein coupled receptors, which are involved in many key physiological functions of the body, including feeding behavior, energy balance, sexual function and behavior, cardiovascular function, kidney function, immune response, etc.<xref ref-type="bibr" rid="article-148945.r7">[7]</xref>&#x000a0;</p>
        <p>Setmelanotide is a type of MC4R agonist with 20-fold less activity at the melanocortin-3 receptor (MC3R) and melanocortin-1 receptor (MC1R). The MC4R can be endogenously activated by the binding of melanocyte-stimulating hormones (MSH), which are involved in responding to acute signal regulations of hunger and satiety.<xref ref-type="bibr" rid="article-148945.r8">[8]</xref><xref ref-type="bibr" rid="article-148945.r9">[9]</xref>&#x000a0;Setmelanotide acts on the MC4R pathway to reverse hyperphagia and promote weight loss through decreased caloric intake and increased energy expenditure.<xref ref-type="bibr" rid="article-148945.r2">[2]</xref><xref ref-type="bibr" rid="article-148945.r10">[10]</xref>&#x000a0;</p>
        <p>The effectiveness of setmelanotide was assessed in phase 3 clinical trials in which 80% of the patients with POMC deficiency and 46% of the patients with LEPR deficiency lost at least 10% of their body weight.<xref ref-type="bibr" rid="article-148945.r11">[11]</xref>&#x000a0;The prevalence of severe obesity in children and adults is more commonly associated with the heterozygous loss of function mutation in MC4R. It is hypothesized that the setmelanotide might increase signaling through the wild-type MC4R allele, thereby leading to weight loss in patients with MC4R deficiency.<xref ref-type="bibr" rid="article-148945.r12">[12]</xref></p>
      </sec>
      <sec id="article-148945.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Setmelanotide is administered subcutaneously and is available as a 1 mL multidose vial with a concentration of 10 mg/mL. The starting dose in the pediatric population between the ages of 6 and &#x0003c; 12 is 1 mg (0.1 mL) injected daily for two weeks. Patients must be simultaneously monitored for side effects, specifically gastrointestinal (GI) and hypersensitivity reactions.<xref ref-type="bibr" rid="article-148945.r5">[5]</xref><xref ref-type="bibr" rid="article-148945.r11">[11]</xref><xref ref-type="bibr" rid="article-148945.r13">[13]</xref>&#x000a0;</p>
        <p>The dose is further adjusted to 2 mg if the initial dose is tolerated. However, if side effects are noted, the dose is decreased to 0.5 mg once daily in pediatric patients. The starting dosage in patients 12 years of age and older is 2 mg (0.2 mL) injected subcutaneously once daily while also monitoring for GI side effects. The dosage is then adjusted from 1 mg (0.1 mL) to 3 mg (0.3 mL), depending on the patient's tolerance.<xref ref-type="bibr" rid="article-148945.r3">[3]</xref><xref ref-type="bibr" rid="article-148945.r13">[13]</xref></p>
        <p>The weight evaluation of the patient is necessary after 12&#x000a0;to 16 weeks of treatment. Recommendations include discontinuing the drug if the patient has not lost either 5% of their baseline body weight or 5% of their baseline body mass index (BMI). Continued treatment with Setmelanotide in patients who exhibit this may not cause significant weight loss.<xref ref-type="bibr" rid="article-148945.r3">[3]</xref><xref ref-type="bibr" rid="article-148945.r11">[11]</xref><xref ref-type="bibr" rid="article-148945.r13">[13]</xref></p>
      </sec>
      <sec id="article-148945.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common side effect of setmelanotide is a hypersensitivity reaction at the injection site, which can lead to blistering, burning, hives, inflammation,&#x000a0;infection, itching, lumps, and discoloration of the skin&#x000a0;<xref ref-type="bibr" rid="article-148945.r3">[3]</xref>. Specific side effects are also associated with setmelanotide therapy, including skin hyperpigmentation, sexual dysfunction, depression, suicidal ideation, etc.<xref ref-type="bibr" rid="article-148945.r3">[3]</xref><xref ref-type="bibr" rid="article-148945.r14">[14]</xref></p>
        <p>Skin hyperpigmentation occurs because the&#x000a0;melanocortin receptors are expressed on&#x000a0;melanocytes, and activation of this receptor leads to the accumulation of melanin, thereby increasing skin pigmentation, independent of ultraviolet light.<xref ref-type="bibr" rid="article-148945.r3">[3]</xref>&#x000a0;The hyperpigmentation of the skin is reversible with the discontinuation of the drug.<xref ref-type="bibr" rid="article-148945.r3">[3]</xref><xref ref-type="bibr" rid="article-148945.r15">[15]</xref>&#x000a0;Theoretically, chronic stimulation of melanocytes may promote the development of melanocytic tumors, including the benign nevus to malignant melanoma.<xref ref-type="bibr" rid="article-148945.r14">[14]</xref>&#x000a0;Therefore, it is important&#x000a0;for regular skin examination before and during the treatment to rule out any underlying malignancy.<xref ref-type="bibr" rid="article-148945.r16">[16]</xref></p>
        <p>Sexual dysfunctions are noted in male and female patients treated with setmelanotide, including spontaneous penile erection in males, and sexual adverse reactions, including labial hypersensitivity in females.<xref ref-type="bibr" rid="article-148945.r17">[17]</xref><xref ref-type="bibr" rid="article-148945.r5">[5]</xref>&#x000a0;This occurs because the agonism of MC4R modulates sexual brain processing which increases sexual desire and&#x000a0;sexual imagery, reduces self-consciousness, and sensitizes the patient to erotic stimuli.<xref ref-type="bibr" rid="article-148945.r18">[18]</xref>&#x000a0;Penile erection, which&#x000a0;lasts more than 4 hours, unrelated to sexual stimulation or orgasm, is called priapism&#x000a0;and is considered a medical emergency because it can cause ischemia of the corpora cavernosa.<xref ref-type="bibr" rid="article-148945.r19">[19]</xref>&#x000a0;</p>
        <p>K&#x000fc;hnen P et al. mention that patients with severe obesity are 30% more likely to have depression than non-obese patients; however, setmelanotide can cause depression and suicidal ideation as a side effect.<xref ref-type="bibr" rid="article-148945.r20">[20]</xref> These patients should consider discontinuing the treatment in case of new onset or worsening depression.<xref ref-type="bibr" rid="article-148945.r5">[5]</xref></p>
        <p>Setmelatonide is not approved&#x000a0;for use in&#x000a0;neonates or infants because it contains&#x000a0;benzyl alcohol as a preservative which can cause fatal adverse reactions, including gasping syndrome.<xref ref-type="bibr" rid="article-148945.r5">[5]</xref>&#x000a0;Gasping syndrome is characterized by&#x000a0;unremitting gasping respirations and may cause anion gap metabolic acidosis, neurologic deterioration, renal failure, convulsions, intraventricular hemorrhage, and cardiovascular collapse.<xref ref-type="bibr" rid="article-148945.r21">[21]</xref><xref ref-type="bibr" rid="article-148945.r22">[22]</xref></p>
      </sec>
      <sec id="article-148945.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Setmelanotide has a low potential for pharmacokinetic drug-drug interactions related to the cytochrome P450 enzyme,&#x000a0;transporters, and plasma protein binding. However, no currently available clinical studies evaluate the risk of patient drug-drug interaction with setmelanotide.<xref ref-type="bibr" rid="article-148945.r23">[23]</xref></p>
        <p>Setmelanotide is contraindicative in pregnancy and should be discontinued during the entire course of the pregnancy unless the benefits outweigh the potential risk to the fetus.<xref ref-type="bibr" rid="article-148945.r23">[23]</xref>&#x000a0;No data is available for the drug-associated risks for major congenital disabilities and miscarriage or adverse maternal or fetal outcomes. However, benzoyl alcohol-associated gasping syndrome may still be a potentially fatal side effect in the unborn fetus.<xref ref-type="bibr" rid="article-148945.r23">[23]</xref><xref ref-type="bibr" rid="article-148945.r24">[24]</xref>&#x000a0;Furthermore, weight loss during pregnancy is generally not recommended as weight loss may increase the risk of fetal comorbidities.<xref ref-type="bibr" rid="article-148945.r24">[24]</xref><xref ref-type="bibr" rid="article-148945.r25">[25]</xref></p>
        <p>Setmelanotide is not recommended for use while breastfeeding as there is no data available on the presence of setmelanotide or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.<xref ref-type="bibr" rid="article-148945.r23">[23]</xref>&#x000a0;However, a nonclinical study showed that setmelanotide is excreted in the milk of nursing rats; hence, it is likely to be present in human milk; therefore, the potential risk to the newborn cannot be excluded.<xref ref-type="bibr" rid="article-148945.r24">[24]</xref></p>
        <p>Setmelanotide is not recommended in pediatric patients six years of age and less and in geriatric patients 65 years of age and over because there is no clinical data available for the efficacy and safety of the drug for these age groups.<xref ref-type="bibr" rid="article-148945.r3">[3]</xref><xref ref-type="bibr" rid="article-148945.r11">[11]</xref><xref ref-type="bibr" rid="article-148945.r13">[13]</xref></p>
        <p>Renal impairment impacts the pharmacokinetics and efficacy of the drug. Hence, setmelanotide is not recommended for patients with moderate to severe renal impairment and is contraindicative in patients with end-stage renal disease (ESRD).<xref ref-type="bibr" rid="article-148945.r23">[23]</xref></p>
        <p>The degradation of subcutaneous or intramuscular&#x000a0;peptides allows for avoiding hepatic enzymes. Degradation of the subcutaneous peptide at the injection site occurs due to protease or peptidase activity in the interstitial space while degradation in the lymphatic system leads&#x000a0;to lower drug bioavailability compared to intravenous administration. However, setmelanotide is not recommended for patients with hepatic impairment as there is no data available for the efficacy and safety of the drug.<xref ref-type="bibr" rid="article-148945.r11">[11]</xref><xref ref-type="bibr" rid="article-148945.r23">[23]</xref></p>
      </sec>
      <sec id="article-148945.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>As mentioned above, monitoring the patient's weight loss periodically, typically after 12 to 16 weeks of therapy in the pediatric and adult populations, is recommended. Evaluation for appropriate growth and maturation in pediatric patients is important as well. Adverse drug reactions (ADR), such as new or worsened depression, hyperpigmentation, and sexual dysfunction in both males and females, should be monitored. In case of severe ADR, setmelanotide therapy should be discontinued.<xref ref-type="bibr" rid="article-148945.r3">[3]</xref><xref ref-type="bibr" rid="article-148945.r11">[11]</xref><xref ref-type="bibr" rid="article-148945.r13">[13]</xref><xref ref-type="bibr" rid="article-148945.r23">[23]</xref></p>
      </sec>
      <sec id="article-148945.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is no known antidote on the market today for the overdose or toxicity of setmelanotide. In the case of an overdose or toxicity, it is recommended to initiate appropriate supportive treatment based on the clinical signs and symptoms of the patient.<xref ref-type="bibr" rid="article-148945.r1">[1]</xref><xref ref-type="bibr" rid="article-148945.r17">[17]</xref><xref ref-type="bibr" rid="article-148945.r26">[26]</xref></p>
      </sec>
      <sec id="article-148945.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of setmelanotide requires both extensive supervision and team collaboration to ensure patient safety and the best possible outcomes. Interprofessional communication among physicians, psychiatrists, pharmacists, and geneticists is crucial. The clinician's role is to determine the screening eligibility of the patient. Since obesity is the number one cause of many ailments, psychiatrists must manage patient concerns to monitor depressive episodes and any new mental health diagnoses.</p>
        <p>Setmelanotide is administered&#x000a0;subcutaneously; therefore, the pharmacist's role is to double-check any contradictions and drug-drug interactions and monitor the long-term effects of the dose. Lastly, the most important role goes to the geneticist, who determines whether the patient is eligible to receive the medication depending on their genetic testing to look for specific deficiencies as described above. All these clinical professionals must constantly communicate with each other regarding the patient's conditions and the therapeutic effects to avoid severe adverse drug reactions (ADR).&#x000a0;</p>
        <p>The management of this medication requires safety in ordering the medication, handling and preparing the subcutaneous administration, proper and detailed documentation, and detailed ongoing evaluations. The administration of drugs should follow strict protocols to ensure patient safety. In efforts to coordinate care for patients on Setmelanotide, the following steps must be taken to ensure positive outcomes:</p>
        <list list-type="bullet">
          <list-item>
            <p>The physician recommends setmelanotide based on eligibility according to the patient's Body Mass Index (BMI) and other risk factors like cardiovascular health, diabetes, hyperphagia, etc. &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The physician then orders genetic testing for the patient to evaluate them for the setmelanotide therapy.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The geneticists must then determine whether the patient is eligible to receive setmelanotide after a&#x000a0;precise&#x000a0;genetic testing report.</p>
          </list-item>
          <list-item>
            <p>The physician/nurse administers setmelanotide via&#x000a0;subcutaneous&#x000a0;therapy while following all strict precautions to keep the patient safe from infection and other adverse events.</p>
          </list-item>
          <list-item>
            <p>The physician and psychiatrist continue to monitor all side effects and long-term management of the drug.</p>
          </list-item>
        </list>
        <p>Setmelanotide&#x000a0;has been known to cause depression and suicidal ideation, as described above.<xref ref-type="bibr" rid="article-148945.r20">[20]</xref>&#x000a0;Patients who are obese may also have existing&#x000a0;psychiatric disorders, including anxiety and substance use disorder which may be exacerbated with this medication.<xref ref-type="bibr" rid="article-148945.r27">[27]</xref>&#x000a0;It is the responsibility of the&#x000a0;clinical team involved in the care of the patient to ask the right questions and monitor for side effects.&#x000a0;&#x000a0;</p>
        <p>Overall, the goal of the interprofessional team is to improve patient outcomes and put patient safety at the forefront. However, the impact goes beyond the clinical outcomes. Among clinicians, geneticists will increase genetic testing with the increased use of this medication.<xref ref-type="bibr" rid="article-148945.r20">[20]</xref>&#x000a0;</p>
        <p>In long-term usage of Setmelanotide, if the medication effects are sub-minimal and the expected weight loss is not achieved, or if the side effects outweigh the therapeutic effects of the drug, then it is the physician's responsibility to reevaluate the drug dosage and concentration while keeping the pharmacokinetics and pharmacodynamics of the drug in mind.</p>
      </sec>
      <sec id="article-148945.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148945&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148945">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/148945/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=148945">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-148945.s11">
        <title>References</title>
        <ref id="article-148945.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markham</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Setmelanotide: First Approval.</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>397</fpage>
            <page-range>397-403</page-range>
            <pub-id pub-id-type="pmid">33638809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ryan</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Setmelanotide: what does it mean for clinical care of patients with obesity?</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>933</fpage>
            <page-range>933-935</page-range>
            <pub-id pub-id-type="pmid">33137294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cignarella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Busetto</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vettor</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy of obesity: An update.</article-title>
            <source>Pharmacol Res</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>169</volume>
            <fpage>105649</fpage>
            <pub-id pub-id-type="pmid">33962014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayers</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Glicksberg</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Garfield</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Longerich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chittenden</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Gulcher</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fiedorek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gottesdiener</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>North</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Schadt</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Van der Ploeg</surname>
                <given-names>LHT</given-names>
              </name>
            </person-group>
            <article-title>Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>103</volume>
            <issue>7</issue>
            <fpage>2601</fpage>
            <page-range>2601-2612</page-range>
            <pub-id pub-id-type="pmid">29726959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polyzos</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Goulis</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Giouleme</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Germanidis</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Goulas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.</article-title>
            <source>Curr Obes Rep</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>166</fpage>
            <page-range>166-179</page-range>
            <pub-id pub-id-type="pmid">35501557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haws</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fletty</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yanovski</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>2133</fpage>
            <page-range>2133-2140</page-range>
            <pub-id pub-id-type="pmid">32627316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hruby</surname>
                <given-names>VJ</given-names>
              </name>
            </person-group>
            <article-title>The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases.</article-title>
            <source>Curr Protein Pept Sci</source>
            <year>2016</year>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>488</fpage>
            <page-range>488-96</page-range>
            <pub-id pub-id-type="pmid">26916163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tao</surname>
                <given-names>YX</given-names>
              </name>
            </person-group>
            <article-title>The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.</article-title>
            <source>Endocr Rev</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>506</fpage>
            <page-range>506-43</page-range>
            <pub-id pub-id-type="pmid">20190196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heyder</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kleinau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Szczepek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kwiatkowski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Speck</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Soletto</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cerd&#x000e1;-Reverter</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Krude</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hnen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Biebermann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Scheerer</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Signal Transduction and Pathogenic Modifications at the Melanocortin-4 Receptor: A Structural Perspective.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>515</fpage>
            <pub-id pub-id-type="pmid">31417496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baldini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Phelan</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>The melanocortin pathway and control of appetite-progress and therapeutic implications.</article-title>
            <source>J Endocrinol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>241</volume>
            <issue>1</issue>
            <fpage>R1</fpage>
            <page-range>R1-R33</page-range>
            <pub-id pub-id-type="pmid">30812013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cl&#x000e9;ment</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van den Akker</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Argente</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bahm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>De Waele</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Farooqi</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Gonneau-Lejeune</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kohlsdorf</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Poitou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Puder</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Swain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wabitsch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hnen</surname>
                <given-names>P</given-names>
              </name>
              <collab>Setmelanotide POMC and LEPR Phase 3 Trial Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>960</fpage>
            <page-range>960-970</page-range>
            <pub-id pub-id-type="pmid">33137293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collet</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Dubern</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mokrosinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mendes de Oliveira</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Henning</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Poitou-Bernert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oppert</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Tounian</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marchelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alili</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Le Beyec</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;pin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lacorte</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gottesdiener</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bounds</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Folster</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>O'Rahilly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stoner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gottesdiener</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Panaro</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Cone</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Cl&#x000e9;ment</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Farooqi</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Van der Ploeg</surname>
                <given-names>LHT</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.</article-title>
            <source>Mol Metab</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>6</volume>
            <issue>10</issue>
            <fpage>1321</fpage>
            <page-range>1321-1329</page-range>
            <pub-id pub-id-type="pmid">29031731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haws</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Yanovski</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alstr&#x000f6;m syndrome: Phase 3 trial design.</article-title>
            <source>Contemp Clin Trials Commun</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>22</volume>
            <fpage>100780</fpage>
            <pub-id pub-id-type="pmid">34013094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Tsch&#x000f6;p</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>O'Rahilly</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Metabolic Precision Medicines: Curing POMC Deficiency.</article-title>
            <source>Cell Metab</source>
            <year>2016</year>
            <month>Aug</month>
            <day>09</day>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>194</fpage>
            <page-range>194-5</page-range>
            <pub-id pub-id-type="pmid">27452145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolf Horrell</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Boulanger</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>D'Orazio</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Melanocortin 1 Receptor: Structure, Function, and Regulation.</article-title>
            <source>Front Genet</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>95</fpage>
            <pub-id pub-id-type="pmid">27303435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Puder</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jahnke</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Krabusch</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Kottner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vogt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andruck</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lechner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Poitou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Krude</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gottesdiener</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cl&#x000e9;ment</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Farooqi</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Wiegand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hnen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Blume-Peytavi</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>A Melanocortin-4 Receptor Agonist Induces Skin and Hair Pigmentation in Patients with Monogenic Mutations in the Leptin-Melanocortin Pathway.</article-title>
            <source>Skin Pharmacol Physiol</source>
            <year>2021</year>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>307</fpage>
            <page-range>307-316</page-range>
            <pub-id pub-id-type="pmid">34058738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Low</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Neuroendocrinology: New hormone treatment for obesity caused by POMC-deficiency.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>627</fpage>
            <page-range>627-628</page-range>
            <pub-id pub-id-type="pmid">27658726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thurston</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hunjan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mills</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Ertl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Phylactou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muzi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Suladze</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Modi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Bassett</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Abbara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldmeier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Comninos</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Dhillo</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder.</article-title>
            <source>J Clin Invest</source>
            <year>2022</year>
            <month>Oct</month>
            <day>03</day>
            <volume>132</volume>
            <issue>19</issue>
            <pub-id pub-id-type="pmid">36189794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alnajjar</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Muneer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in understanding and treating priapism.</article-title>
            <source>Fac Rev</source>
            <year>2022</year>
            <volume>11</volume>
            <fpage>23</fpage>
            <pub-id pub-id-type="pmid">36118326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>K&#x000fc;hnen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wabitsch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>von Schnurbein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chirila</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mallya</surname>
                <given-names>UG</given-names>
              </name>
              <name>
                <surname>Callahan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gnanasakthy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poitou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Krabusch</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cl&#x000e9;ment</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2022</year>
            <month>Feb</month>
            <day>05</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <pub-id pub-id-type="pmid">35123544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCloskey</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Gershanik</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lertora</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Toxicity of benzyl alcohol in adult and neonatal mice.</article-title>
            <source>J Pharm Sci</source>
            <year>1986</year>
            <month>Jul</month>
            <volume>75</volume>
            <issue>7</issue>
            <fpage>702</fpage>
            <page-range>702-5</page-range>
            <pub-id pub-id-type="pmid">3761172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gershanik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boecler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ensley</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McCloskey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The gasping syndrome and benzyl alcohol poisoning.</article-title>
            <source>N Engl J Med</source>
            <year>1982</year>
            <month>Nov</month>
            <day>25</day>
            <volume>307</volume>
            <issue>22</issue>
            <fpage>1384</fpage>
            <page-range>1384-8</page-range>
            <pub-id pub-id-type="pmid">7133084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahmood</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pettinato</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Peptides: When Is the Assessment of Certain Factors Warranted?</article-title>
            <source>Antibodies (Basel)</source>
            <year>2021</year>
            <month>Dec</month>
            <day>21</day>
            <volume>11</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">35076485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <article-title>Setmelanotide Acetate.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2021</year>
            <month>Mar</month>
            <day>31</day>
            <volume>78</volume>
            <issue>8</issue>
            <fpage>652</fpage>
            <page-range>652-655</page-range>
            <pub-id pub-id-type="pmid">33787829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cox Bauer</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Bernhard</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Merrill</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Maternal and neonatal outcomes in obese women who lose weight during pregnancy.</article-title>
            <source>J Perinatol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>278</fpage>
            <page-range>278-83</page-range>
            <pub-id pub-id-type="pmid">26741574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <article-title>Setmelanotide (Imcivree) for rare genetic forms of obesity.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2021</year>
            <month>Jul</month>
            <day>26</day>
            <volume>63</volume>
            <issue>1629</issue>
            <fpage>e3</fpage>
            <page-range>e3-e4</page-range>
            <pub-id pub-id-type="pmid">34544109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148945.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simon</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Von Korff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miglioretti</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Crane</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>van Belle</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Association between obesity and psychiatric disorders in the US adult population.</article-title>
            <source>Arch Gen Psychiatry</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>63</volume>
            <issue>7</issue>
            <fpage>824</fpage>
            <page-range>824-30</page-range>
            <pub-id pub-id-type="pmid">16818872</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
